NewsBenzingaKeros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial Keros Therapeutics Expects $20M Development Milestone Payment Under Elritercept License Agreement Of With Takeda After Dosing Of First Patient In The ELRiSE MF Clinical Trial Benzinga 2026.09.29 12:04 (GMT+0) Open on Benzinga Other news If You Invested $1000 In Watts Water Technologies Stock 15 Years Ago, You Would Have This Much Today 12 Consumer Discretionary Stocks Moving In Friday's After-Market Session 12 Health Care Stocks Moving In Friday's After-Market Session 12 Industrials Stocks Moving In Friday's After-Market Session 12 Information Technology Stocks Moving In Friday's After-Market Session Here’s How Much You Would Have Made Owning Enpro Stock In The Last 20 Years
